Table 1 Laboratory findings in COVID-19 patients
Laboratory items | Normal range | All patients (n = 37) | Severe (n = 9) | Non-severe (n = 28) | P value |
|---|---|---|---|---|---|
White blood cell (× 109/L) | 3.5–9.5 | 5.61 (4.21–10.21) | 11.40 (7.20–15.59) | 5.45 (4.13–7.11) | 0.001 |
Neutrophil (× 109/L) | 1.8–6.3 | 3.58 (2.39–8.07) | 10.81(5.17–13.29) | 3.30 (2.35–5.20) | 5 × 10–4 |
Lymphocyte (× 109/L) | 1.1–3.2 | 1.02 (0.68–1.70) | 0.78 (0.46–0.96) | 1.22 (0.89–1.83) | 0.053 |
Monocyte (× 109/L) | 0.1–0.6 | 0.54 (0.34–0.73) | 0.78 (0.10–1.33) | 0.54 (0.35–0.70) | 0.043 |
Neutrophil (%) | 40–75 | 65.40 (56.40–84.20) | 84.20 (74.20–87.95) | 60.80 (54.98–76.43) | 0.002 |
Lymphocyte (%) | 20–50 | 23.00 (11.05–31.20) | 11.20 (5.75–18.95) | 25.10 (14.23–32.03) | 0.005 |
Monocyte (%) | 3–10 | 8.50 (6.05–11.00) | 6.00 (2.40–8.45) | 9.60 (7.33–11.78) | 0.005 |
Lactate dehydrogenase (U/L) | 120–250 | 178.0 (155.0–208.7) | 334.7 (191.0–476.5) | 163.6 (149.4–185.5) | 0.005 |
Alkaline Phosphatase (U/L) | 45–125 | 61.70 (46.85–72.45) | 59.13 (42.90–61.95) | 68.15 (48.50–73.28) | 0.091 |
Total bile acid (μmol/L) | 0–12 | 4.15 (2.15–5.92) | 5.48 (2.33–6.99) | 0.80 (2.07–5.65) |  < 1 × 10–4 |
r-glutaminase (U/L) | 10–60 | 28.28 (14.90–85.74) | 100.10 (23.25–187.60) | 27.25 (11.98–43.60) | 0.011 |
Adenosine deaminase (U/L) | 4–24 | 9.22 (8.04–11.47) | 12.04 (10.11–15.70) | 8.87 (7.87–10.11) |  < 1 × 10–4 |
Procalcitonin (ng/ml) |  < 0.046 | 0.10 (0.04–0.70) | 0.80 (0.42–3.12) | 0.06 (0.04–0.10) | 0.034 |
C-reactive protein (mg/L) | 0–10 | 25.37 (1.97–58.70) | 70.13 (58.70–168.50) | 8.39 (1.70–33.47) |  < 1 × 10–4 |
D-dimer (ng/ml) |  < 0.5 | 340.3 (175.0–485.0) | 416.0 (350.0–910.0) | 290.0 (150.0–445.0) | 0.050 |
CD3+T (%) | 50–84 | 73.67 (60.61–79.61) | 65.23 (56.16–75.80) | 75.05 (62.44–80.84) | 0.312 |
CD3+T cell count | 955–2,860 | 887.0 (586.3–1,509.0) | 991.0 (618.0–1,216.0) | 880.0 (571.5–1,553.0) | 0.952 |
CD3+CD4+T (%) | 27–51 | 41.31 (31.04–49.54) | 47.71 (28.48–50.06) | 41.03 (32.04–49.06) | 0.716 |
CD3+CD4+T cell count | 550–1,440 | 501.0 (335.8–673.8) | 612.0 (313.0–682.0) | 499.0 (353.5–647.5) | 0.479 |
CD3+CD8+T (%) | 15–44 | 24.41 (17.10–30.37) | 24.41 (17.10–30.37) | 21.56 (17.59–31.49) | 0.899 |
CD3+CD8+T cell count | 320–1,250 | 319.5 (192.5–523.0) | 338.0 (301.0–540.0) | 282.0 (170.0–512.0) | 0.884 |
CD3−CD16/56+ NK (%) | 7–40 | 12.48 (8.78–17.87) | 9.37 (5.55–30.43) | 13.06 (9.67–17.29) | 0.809 |
CD3−CD16/56+ cell count | 150–1,100 | 174.5 (121.3–226.0) | 164.0 (76.0–335.0) | 185.0 (133.5–219.5) | 0.554 |
CD3−CD19+ B (%) | 5–18 | 11.63 (8.02–17.50) | 18.36 (11.57–22.38) | 11.40 (7.51–13.70) | 0.089 |
CD3−CD19+ B cell count | 90–560 | 141.0 (97.5–300.8) | 250.0 (127.0–354.0) | 107.0 (96.0–259.5) | 0.123 |